FibroGen terminates prior HiFiBiO license deal, licenses anti-CCR8 and anti-Gal-9 assets

KYNTRA BIO, INC.

Terminated Exclusive License and Option Agreement with HiFiBiO dated June 2021, as amended Feb 2024.
Licensed anti-CCR8 (FG-3175) and anti-Gal-9 (FG-3165) intellectual property to HiFiBiO.
Eligible for mid single-digit to low double-digit share of HiFiBiO's sublicense revenues and low double-digit share of commercial royalties.
If HiFiBiO commercializes either asset, FibroGen receives single-digit royalties on worldwide net sales.

item 1.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.